Frazier Life Sciences Management, L.P.
Reported holdings as of Q2 2026, from 18 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| MIRUM PHARMACEUTICALS INC | MIRM | $899.1M | 7,679,684 | +1.32pp | 18q | HELD | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $613.0M | 18,088,902 | -0.61pp | 15q | +6.8%+$38.8M | |
| ERASCA INC | ERAS | $457.5M | 24,975,188 | -0.31pp | 9q | +1.2%+$5.5M | |
| MBX BIOSCIENCES INC | MBX | $367.2M | 6,652,013 | +2.89pp | 8q | HELD | |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | $258.9M | 9,874,511 | -0.35pp | 18q | HELD | |
| TREVI THERAPEUTICS INC | TRVI | $185.4M | 9,939,447 | +0.99pp | 17q | HELD | |
| KRYSTAL BIOTECH INC | KRYS | $178.9M | 481,307 | +0.70pp | 18q | HELD | |
| MAZE THERAPEUTICS INC | MAZE | $150.2M | 5,032,915 | -0.24pp | 6q | +10.2%+$13.9M | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $135.3M | 12,466,489 | -0.62pp | 18q | HELD | |
| PALVELLA THERAPEUTICS INC NE | PVLA | $134.8M | 882,400 | +0.11pp | 7q | HELD | |
| BRIDGEBIO PHARMA INC | BBIO | $115.3M | 1,548,139 | -4.08pp | 14q | -55.1%-$141.5M | |
| DISC MEDICINE INC | IRON | $99.1M | 1,354,852 | -0.07pp | 13q | HELD | |
| CYTOKINETICS INC | CYTK | $98.8M | 1,159,879 | +0.18pp | 5q | HELD | |
| DYNE THERAPEUTICS INC | DYN | $70.0M | 3,153,082 | +0.05pp | 6q | HELD | |
| ASCENDIS PHARMA A/S | ASND | $60.1M | 225,155 | +0.52pp | 8q | +68.9%+$24.5M | |
| SAVARA INC | SVRA | $59.9M | 9,720,852 | -0.06pp | 12q | HELD | |
| PARABILIS MEDICINES INC | PBLS | $52.6M | 1,920,805 | - | new | NEW | |
| AURA BIOSCIENCES INC | AURA | $50.4M | 7,100,000 | +0.22pp | 5q | +39.2%+$14.2M | |
| ACHIEVE LIFE SCIENCE INC | ACHV | $49.7M | 7,614,836 | - | new | NEW | |
| VOR BIOPHARMA INC | VOR | $46.8M | 2,543,939 | -0.15pp | 3q | HELD | |
| ALLOGENE THERAPEUTICS INC | ALLO | $46.7M | 22,446,668 | +0.78pp | 10q | +491.2%+$38.8M | |
| TARSUS PHARMACEUTICALS INC | TARS | $45.9M | 728,644 | -0.32pp | 18q | HELD | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $40.1M | 4,009,240 | -0.11pp | 2q | HELD | |
| ALKERMES PLC | ALKS | $36.7M | 700,647 | +0.16pp | 8q | HELD | |
| ACADIA PHARMACEUTICALS INC | ACAD | $36.4M | 1,438,198 | -0.03pp | 4q | HELD | |
| ZAI LAB LTD | ZLAB | $36.1M | 1,902,320 | -0.13pp | 6q | HELD | |
| MANNKIND CORP | MNKD | $28.1M | 6,600,000 | +0.24pp | 3q | +11.9%+$3.0M | |
| DESIGN THERAPEUTICS INC | DSGN | $26.2M | 1,809,854 | - | new | NEW | |
| ACLARIS THERAPEUTICS INC | ACRS | $26.1M | 4,925,374 | +0.09pp | 2q | HELD | |
| SHATTUCK LABS INC | STTK | $26.0M | 3,750,000 | - | new | NEW | |
| KAILERA THERAPEUTICS INC | KLRA | $24.2M | 1,100,000 | - | new | NEW | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $24.2M | 1,000,000 | +0.10pp | 2q | HELD | |
| LEXEO THERAPEUTICS INC | LXEO | $22.5M | 4,824,725 | -0.16pp | 8q | +9.0%+$1.9M | |
| RELAY THERAPEUTICS INC | RLAY | $19.0M | 1,015,693 | - | new | NEW | |
| EVOLUS INC | EOLS | $18.3M | 2,630,665 | +0.12pp | 5q | HELD | |
| IMMUNOCORE HLDGS PLC | IMCR | $15.4M | 484,782 | -0.04pp | 9q | HELD | |
| VALNEVA SE | VALN | $12.0M | 2,291,666 | -0.11pp | 5q | HELD | |
| NEWAMSTERDAM PHARMA COMPANY | NAMSW | $10.7M | 500,333 | -0.03pp | 15q | HELD | |
| AUTOLUS THERAPEUTICS LTD | AUTL | $7.1M | 4,447,910 | flat | 18q | HELD | |
| XILIO THERAPEUTICS INC | XLO | $4.0M | 422,505 | flat | 2q | HELD | |
| IBIO INC | IBIO | $3.4M | 1,953,467 | -0.02pp | 3q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $4.5B | 98.3% |
| Not classified | $76.8M | 1.7% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $4.6B | 41 | 6 | 8 | 1 | 3 | 73.6% | 45 |
| Q1 2026 | $3.9B | 38 | 4 | 8 | 9 | 6 | 73.5% | 45 |
| Q4 2025 | $3.7B | 40 | 5 | 6 | 8 | 12 | 71.0% | 44 |
| Q3 2025 | $3.3B | 47 | 4 | 10 | 6 | 6 | 69.5% | 45 |
| Q2 2025 | $2.5B | 49 | 8 | 16 | 5 | 6 | 67.8% | 45 |
| Q1 2025 | $2.2B | 47 | 4 | 9 | 8 | 7 | 70.2% | 45 |
| Q4 2024 | $2.4B | 50 | 3 | 12 | 8 | 6 | 66.5% | 49 |
| Q3 2024 | $2.5B | 53 | 8 | 13 | 5 | 4 | 59.9% | 46 |
| Q2 2024 | $2.1B | 49 | 8 | 13 | 4 | 9 | 62.0% | 46 |
| Q1 2024 | $2.4B | 50 | 7 | 12 | 6 | 6 | 58.6% | 45 |
| Q4 2023 | $1.9B | 49 | 5 | 13 | 3 | 7 | 59.4% | 45 |
| Q3 2023 | $1.5B | 51 | 7 | 10 | 4 | 4 | 63.1% | 45 |
| Q2 2023 | $1.7B | 48 | 4 | 11 | 8 | 5 | 66.8% | 45 |
| Q1 2023 | $1.4B | 49 | 8 | 6 | 4 | 3 | 65.3% | 45 |
| Q4 2022 | $1.6B | 44 | 7 | 9 | 5 | 6 | 66.4% | 38 |
| Q3 2022 | $1.3B | 43 | 7 | 10 | 6 | 5 | 67.1% | 45 |
| Q2 2022 | $1.1B | 41 | 2 | 8 | 8 | 3 | 68.2% | 41 |
| Q1 2022 | $1.2B | 42 | 0 | 0 | 0 | 0 | 60.2% | 46 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.